Company Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.
The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis.
It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Country | United States |
| Founded | 1999 |
| IPO Date | Aug 11, 2009 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 93 |
| CEO | A. Kazimi |
Contact Details
Address: 1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203 United States | |
| Phone | 615 255 0068 |
| Website | cumberlandpharma.com |
Stock Details
| Ticker Symbol | CPIX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001087294 |
| CUSIP Number | 230770109 |
| ISIN Number | US2307701092 |
| Employer ID | 62-1765329 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| A. J. Kazimi MBA | Founder, Chairman, President and Chief Executive Officer |
| John Michael Hamm C.M.A. | Vice President Accounting and Finance and Chief Financial Officer |
| James Lowrance Herman | Vice President of Trade and Distribution and Chief Compliance Officer |
| Christopher T. Bitterman | Vice President of Sales and Marketing |
| Todd M. Anthony | Vice President of Organizational Development |
| Jean W. Marstiller | Senior Vice President of Administrative Services and Corporate Secretary |
| Adam S. Mostafa | Managing Director of Banking and Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2026 | ARS | Filing |
| Mar 9, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 9, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 9, 2026 | 10-K | Annual Report |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 9, 2026 | SCHEDULE 13G | Filing |
| Feb 4, 2026 | 8-K | Current Report |
| Nov 24, 2025 | 8-K | Current Report |
| Nov 7, 2025 | 10-Q | Quarterly Report |
| Nov 4, 2025 | 8-K | Current Report |